Equities

Haleon PLC

HLN:LSE

Haleon PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)396.60
  • Today's Change6.50 / 1.67%
  • Shares traded35.31m
  • 1 Year change19.66%
  • Beta--
Data delayed at least 20 minutes, as of Sep 27 2024 17:01 BST.
More ▼

Profile data is unavailable for this security.

About the company

Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

  • Revenue in GBP (TTM)11.26bn
  • Net income in GBP1.09bn
  • Incorporated2021
  • Employees24.00k
  • Location
    Haleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
  • Phone+44 19 3282 2000
  • Websitehttps://www.haleon.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Biogen Inc7.23bn866.27m21.31bn7.57k21.31bn7.57k
Bayer AG39.32bn-1.06bn21.71bn96.57k21.71bn96.57k
Otsuka Holdings Co Ltd11.46bn666.82m24.04bn34.39k24.04bn34.39k
UCB SA4.55bn200.32m26.46bn9.08k26.46bn9.08k
Jiangsu Hengrui Pharmaceuticals Co Ltd2.69bn578.64m30.10bn19.61k30.10bn19.61k
Haleon PLC11.26bn1.09bn35.14bn24.00k35.14bn24.00k
Takeda Pharmaceutical Co Ltd23.21bn788.30m35.34bn49.28k35.34bn49.28k
Sun Pharmaceutical Industries Ltd4.39bn927.87m39.79bn43.00k39.79bn43.00k
Data as of Sep 27 2024. Currency figures normalised to Haleon PLC's reporting currency: UK Pound GBX

Institutional shareholders

17.01%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 01 Sep 2024238.18m2.61%
The Vanguard Group, Inc.as of 01 Sep 2024234.47m2.57%
MFS International (UK) Ltd.as of 01 Sep 2024152.24m1.67%
BlackRock Fund Advisorsas of 01 Sep 2024151.91m1.67%
BlackRock Investment Management (UK) Ltd.as of 01 Sep 2024149.25m1.64%
Norges Bank Investment Managementas of 01 Sep 2024142.60m1.56%
Harding Loevner LPas of 01 Sep 2024132.71m1.45%
First Eagle Investment Management LLCas of 01 Sep 2024128.80m1.41%
GIC Pte Ltd. (Investment Management)as of 01 Sep 2024111.48m1.22%
Legal & General Investment Management Ltd.as of 01 Sep 2024110.07m1.21%
More ▼
Data from 30 Jun 2024 - 19 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.